“Peripheral antinociception of RES intermediate‐dose (50 &mgr;g/paw) was increased by: (i) bestatin , inhibitor of endogenous opioid degradation involved‐enzymes; (ii) MAFP, inhibitor of anandamide amidase; (iii) JZL184, inhibitor of 2‐arachidonoylglycerol degradation involved‐enzyme; (iv) VDM11, endocannabinoid reuptake inhibitor.”